HoxD10 Inhibitors
The chemical class known as HoxD10 inhibitors encompasses a variety of compounds that interface with cellular signaling pathways or gene expression mechanisms to influence the activity of the HoxD10 protein. These compounds are not direct inhibitors of the HoxD10 protein but act upstream to modulate the pathways that govern the expression or function of HoxD10. The majority of these compounds interfere with kinase signaling pathways, such as the PI3K/AKT/mTOR pathway (e.g., LY294002, Rapamycin), the MAPK/ERK pathway (e.g., U0126, PD98059, SP600125), and the TGF-beta/SMAD pathway (SB431542). These pathways are critical for various cellular processes including cell growth, differentiation, and apoptosis, all of which can have downstream effects on the expression of Hox genes.
Other compounds in this class target pathways involved in cell fate determination and patterning, such as the Hedgehog pathway (Cyclopamine), the Notch pathway (DAPT), and the Wnt/β-catenin pathway (ICG-001, LGK-974). Inhibition of these pathways can lead to changes in gene expression profiles within the cell, which includes the modulation of HoxD10 expression. Retinoic acid and its derivatives are well-known for their role in regulating gene expression, including that of Hox genes, by binding to nuclear receptors that can directly interact with DNA and alter transcription. Additionally, compounds like Y-27632 affect the cytoskeleton and cellular structure, potentially leading to indirect effects on gene expression. Each compound on this list has a unique mechanism of action, but all converge on the potential modulation of HoxD10 activity by altering the cell's regulatory network and intracellular signaling, affecting the protein's expression or function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can alter the AKT signaling pathway, potentially impacting HoxD10 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can affect Hox gene expression by altering cell growth and proliferation signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor that may influence cytoskeleton organization and thereby affect the cell environment and potentially the expression of genes such as HoxD10. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
Notch pathway inhibitor, which is involved in cell differentiation and could influence HoxD10 expression indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor impacting the MAPK/ERK pathway and potentially HoxD10 gene expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Inhibitor of the TGF-beta receptor, can modify the SMAD signaling pathway which is known to intersect with Hox gene regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, part of the MAPK pathway, which can regulate a variety of transcription factors and may indirectly affect HoxD10 expression. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
Inhibitor of the Wnt/β-catenin pathway by targeting Porcupine, an O-acyltransferase involved in Wnt processing and secretion, thereby potentially modulating HoxD10 gene expression. | ||||||